Interview with Margaret Hamburg

FDA Commissioner Margaret Hamburg talks about new regulatory tools, surrogate endpoints, ebola, and more on Engaging Innovation.

Read More

2014 Conference on Clinical Cancer Research

Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.

Read More

New collaborative clinical trial launches

Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP

Read More

Accelerating Science and Technology

Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.

Read More

Download the 2013 Annual Report

Friends of Cancer Research's 2013 Annual Report is now available for download.

Read More

Breakthrough Therapies In Action

Eleven novel drugs have already been approved through the FDA's Breakthrough Therapy program.

Read More

Friends Hosts Breakthrough Briefing

Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing

Read More
View More

Recent and Upcoming Events

Breakthrough Designations

View More

Ranibizumab (Lucentis) - (Genentech)

for the treatment of diabetic retinopathy


Ixazomib - (Takeda Therapeutics)

for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis


JCAR015 - (Juno Therapeutics)

for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia

Recent Blogs

FDA Commissioner Dr. Margaret Hamburg commented on pressing issues in drug development and regulation.


"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."

Ellen Sigal,
Chair, Friends of Cancer Research